A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus

Inclusion Criteria: * Men and women between the ages of 18 and 65 years old * Diagnosis of SLE * Stable disease; defined as no change in SLE therapy within the previous 30 days. Up to 5 mg/day incremental changes of prednisone therapy is allowed during the 30 days prior to randomization * SLE disease duration of at least 1 year, as diagnosed by a physician Exclusion Criteria: * Current renal disease * Signs or symptoms of viral or bacterial infection within 30 days of enrollment * Any disorder (including psychiatric), condition or clinically significant disease (other than a diagnosis of SLE) that would interfere the study evaluation, completion and/or procedures per the investigator's discretion * Administration of more than 10 mg/day prednison (or equivalent) in the 30 days prior to randomization